Advances in Pleural and Peritoneal Mesothelioma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 20 June 2026 | Viewed by 821
Special Issue Editor
Interests: molecular pathology; lung cancer; mesothelioma; precision medicine; predictive biomarkers; molecular tests; next-generation sequencing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pleural and peritoneal mesotheliomas are rare, asbestos-related malignancies with an extremely poor prognosis and limited treatment options. Mesothelioma is a challenging tumor to diagnose and treat, and, currently, the histotype is the most reliable prognostic factor. However, recent studies on pleural mesothelioma have revealed genomic features that impact diagnosis, treatment response, and prognosis definition. Whereas there is data available regarding molecular characterization of peritoneal mesothelioma.
Molecular studies of both pleural and peritoneal mesothelioma are strongly warranted to define biomarkers useful to improve clinical practice.
This Special Issue welcomes original articles, reviews, and meta-analyses underlying advances in pleural and peritoneal mesothelioma from genetic landscape to treatment.
I look forward to receiving your contributions.
Dr. Rossella Bruno
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pleural mesothelioma
- peritoneal mesothelioma
- differential diagnosis
- biomarkers
- next-generation sequencing
- gene expression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
